Pipeline Developments, Product Recalls, Clinical Trial Results, Recognitions, and New Appointments - Research Report on Johnson & Johnson, Amgen, Regeneron, UnitedHealth, and Bristol-Myers

NEW YORK, September 18, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Investors' Reports announced new research reports highlighting Johnson & Johnson (NYSE: JNJ), Amgen, Inc. (NASDAQ: AMGN), Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), UnitedHealth Group Inc. (NYSE: UNH), and Bristol-Myers Squibb Co. (NYSE: BMY). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Johnson & Johnson Research Report

On September 12, 2013, the New York Times reported that Janssen, the pharmaceutical unit of Johnson & Johnson (Johnson & Johnson), informed doctors and patients on September 11, 2013, that it was recalling one lot of Risperdal Consta, an injectable antipsychotic treatment, after routine testing turned up evidence of mold. Further, the New York Times reported that a week earlier, Johnson & Johnson had recalled 200,000 bottles of liquid Motrin for infants because they may contain tiny particles of plastic. Johnson & Johnson stated that in both cases risk to patients was low and it had received no reports of serious harm. The Full Research Report on Johnson & Johnson - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-09-16/JNJ]

--

Amgen, Inc. Research Report

On September 11, 2013, Amgen, Inc. (Amgen) announced the publication of a biomarker analysis of Vectibix (panitumumab) in combination with FOLFOX, a type of oxaliplatin-based chemotherapy, for the first-line treatment of patients with metastatic colorectal cancer (mCRC). According to the analysis published in the New England Journal of Medicine, RAS mutations (mutations found in exons 2, 3, and 4 of KRAS and NRAS), beyond the known KRAS exon 2 mutations, predict lack of response to Vectibix in combination with FOLFOX. Jean-Yves Douillard, M.D., Ph.D., Professor of Medical Oncology, Centre R. Gauducheau, France and PRIME Trial Lead Investigator and Author, stated, "While the KRAS exon 2 biomarker is well-known and has facilitated selection of patients more likely to respond to anti-EGFR treatment, we found that there were still some patients who didn't benefit from treatment. This analysis is important as it furthers our understanding of tumor genetics and allows physicians to more accurately match patients to effective treatments." The Full Research Report on Amgen, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-09-16/AMGN]

--

Regeneron Pharmaceuticals Inc. Research Report

On September 10, 2013, Regeneron Pharmaceuticals Inc. (Regeneron) announced that Robert E. Landry has been appointed as Senior Vice President, Finance. In addition, the Company stated that Mr. Landry will take on the position of CFO of Regeneron on October 1, 2013. According to the Company, Mr. Landry will be responsible for all financial functions, including Controller's, Treasury, Financial Planning, Tax, and Internal Audit. Regeneron added that its current Chief Financial Officer, Murray A. Goldberg, will transition to a new role as Senior Vice President, Administration, in preparation for his retirement at the end of 2014. The Company further reported that Goldberg will continue to be responsible for Alliance Management and various administrative functions. The Full Research Report on Regeneron Pharmaceuticals Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-09-16/REGN]

--

UnitedHealth Group Inc. Research Report

On September 13, 2013, UnitedHealth Group Inc. (UnitedHealth) announced that it has been included in the Dow Jones Sustainability North America Index (DJSI NA) and the Dow Jones Sustainability World Index (DJSI W). The Company said that it ranked first among its peers in health care providers and services industry sector for corporate citizenship and philanthropy, partnerships toward sustainable health care, codes of conduct and compliance, and operational eco-efficiency. Jeannine M. Rivet, Executive Vice President, UnitedHealth, said, "The people of this enterprise are dedicated to a culture of integrity, compassion, relationships, innovation and performance. Our focus on achieving these defining traits informs the decisions we make and guides our businesses in serving the health benefits and services needs of millions of consumers, physicians and other care providers, employers, government and other benefit sponsors. We are honored to be recognized for the work we do every day to make high-quality health care more accessible and affordable for more people." The Full Research Report on UnitedHealth Group Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-09-16/UNH]

--

Bristol-Myers Squibb Co. Research Report

On September 12, 2013, Bristol-Myers Squibb Co. (Bristol-Myers) reported results from the Phase 3, randomized, double-blind clinical trial (Study 043) comparing Yervoy 10 mg/kg (ipilimumab) (n=399) to placebo (n=400) following radiation in patients with advanced metastatic castration-resistant prostate cancer (mCRPC) who have received prior treatment with docetaxel.  The Company revealed that the study's primary endpoint of overall survival (OS) did not reach statistical significance (HR = 0.85; 95% CI = 0.72-1.00; p = 0.053). Nevertheless, the Company stated that anti-tumor activity was observed across some efficacy endpoints, including progression free-survival. W. R. Gerritsen, M.D., Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, said, "Although the study did not meet its primary endpoint, clinical activity was observed in this Phase 3 trial with a suggestion of greater activity in those with less advanced castration-resistant prostate cancer. These results offer important insights for ongoing and future studies of Yervoy in prostate cancer, including a second large trial of Yervoy in patients with less advanced disease." The Full Research Report on Bristol-Myers Squibb Co. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-09-16/BMY]

----

EDITOR NOTES:

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
5. For any urgent concerns or inquiries, please contact us at [email protected].
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Namrata Maheshwari, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

InvestorsReports.com

SOURCE Investors' Reports